Open AccessEfficacy and Tolerability of Triple‐Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: A Subgroup Analysis of Patients Stratified by Hypertension Severity, Age, Sex, and Obesity
Author(s) -
Kreutz Reinhold,
Ammentorp Bettina,
Laeis Petra,
Sierra Alejandro
Publication year - 2014
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.12408
Subject(s) - medicine , hydrochlorothiazide , olmesartan , amlodipine , blood pressure , tolerability , urology , body mass index , placebo , combination therapy , subgroup analysis , adverse effect , confidence interval , alternative medicine , pathology
This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide ( HCTZ ) to olmesartan ( OLM )/amlodipine ( AML ) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity. A total of 2690 patients, aged 18 years and older, with seated blood pressure (Se BP ) ≥160/100 mm Hg received placebo or OLM / AML 20/5 mg, 40/5 mg, or 40/10 mg during a 2‐week, double‐blind, run‐in period, after which they were allocated to one of eight treatment groups with the same OLM / AML dose or with HCTZ 12.5 mg or 25 mg added for 8 weeks. By week 10, greater reductions in Se BP were observed in each OLM / AML / HCTZ group ( P <.05, respectively) compared with the corresponding dual dose. Adding HCTZ increased blood pressure–lowering efficacy in all subgroups, with a higher proportion of blood pressure goal achievement vs dual therapy. OLM / AML / HCTZ reduced Se BP to a greater extent than OLM / AML in patients with moderate to severe hypertensive; this was unaffected by baseline hypertension severity, age, sex, and obesity.